항-표피성장인자수용체 단클론항체와 DNA 토포이소머라제 억제제에 의한 마우스 모델에서의 타액선 선낭암종 성장 억제
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody and DNA topoisomerase inhibitor reduce growth of salivary adenoid cystic carcinoma in a murine model
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Introduction: Epidermal growth factor receptor (EGFR) is expressed in human epithelial tumors including salivary cancers, and known to be correlated with tumor progression and poor clinical courses in some epithelial tumors. In this study, we determined the therapeutic effect of the anti-EGFR monoclonal antibody Erbitux (C225, cetuximab) in combination with the DNA topoisomerase I inhibitor irinotecan (CPT-11) on human salivary adenoid cystic carcinoma (SACC) cells growing in nude mice. Materials and Methods: At first, immunocytochemical analysis for the expression of EGFR and phosphorylated EGFR (pEGFR) on a human salivary ACC cell line (ACC3). To determine the in vivo effects of Erbitux and CPT-11, nude mice with orthotopic parotid tumors were randomized to receive intraperitoneal Erbitux (1 mg) two times per week, intraperitoneal Irinotecan (50 mg/kg) once per week, Erbitux plus CPT-11, or placebo. (control) Tumor volume and weight were measured. And mechanisms of in vivo activity of Erbitux and/or CPT-11 were determined by immunohistochemical/immunofluorescent analyses. Results: Immunocytochemical staining of ACC3 demonstrated that EGFR was expressed and phosphorylated. CPT-11 inhibited ACC tumor growth in nude mice. Tumors of mice treated with CPT-11 and CPT-11 plus Erbitux exhibited increased tumor cell apoptosis and decreased microvessel density,which correlated with a decrease in the tumor volume in nude mice. But, CPT-11 seems not to be synergistic with Erbitux in our ACC3 model system. Conclusion: These results suggest that anti-EGFR monoclonal antibody and the DNA topoisomerase I inhibitor will be effective in the treatment of recurred or metastatic lesions of salivary ACC.
Abstract
Introduction: Epidermal growth factor receptor (EGFR) is expressed in human epithelial tumors including salivary cancers, and known to be correlated with tumor progression and poor clinical courses in some epithelial tumors. In this study, we determined the therapeutic effect of the anti-EGFR monoclonal antibody Erbitux (C225, cetuximab) in combination with the DNA topoisomerase I inhibitor irinotecan (CPT-11) on human salivary adenoid cystic carcinoma (SACC) cells growing in nude mice. Materials and Methods: At first, immunocytochemical analysis for the expression of EGFR and phosphorylated EGFR (pEGFR) on a human salivary ACC cell line (ACC3). To determine the in vivo effects of Erbitux and CPT-11, nude mice with orthotopic parotid tumors were randomized to receive intraperitoneal Erbitux (1 mg) two times per week, intraperitoneal Irinotecan (50 mg/kg) once per week, Erbitux plus CPT-11, or placebo. (control) Tumor volume and weight were measured. And mechanisms of in vivo activity of Erbitux and/or CPT-11 were determined by immunohistochemical/immunofluorescent analyses. Results: Immunocytochemical staining of ACC3 demonstrated that EGFR was expressed and phosphorylated. CPT-11 inhibited ACC tumor growth in nude mice. Tumors of mice treated with CPT-11 and CPT-11 plus Erbitux exhibited increased tumor cell apoptosis and decreased microvessel density,which correlated with a decrease in the tumor volume in nude mice. But, CPT-11 seems not to be synergistic with Erbitux in our ACC3 model system. Conclusion: These results suggest that anti-EGFR monoclonal antibody and the DNA topoisomerase I inhibitor will be effective in the treatment of recurred or metastatic lesions of salivary ACC.
참고문헌 (35)
- Licitra L, "Head and neck tumors other than squamous cell carcinoma", Curr Opin Oncol, 16, pp.236~241 (2004)
- Jones AS, "Adenoid cystic carcinoma of the head and neck", Clin Otolaryngol, 22, pp.434~443 (1997)
- Laurie SA, "Systemic therapy in the palliative management of advanced salivary grand cancers", J Clin Oncol, 24, pp.2673~2678 (2006)
- Airoldi M, "Update and perspectives on non-surgical treatment of salivary gland malignancies", Acta Otorhinolaryngol Ital, 23, pp.368~376 (2003)
- Kuwai T, "Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors", Neoplasia, 10, pp.489~500 (2008)
- Herbst RS, "IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer", Semin Oncol, 29, pp.18~30 (2002)
- 박영욱, "타액선 선양낭성암종에서 상피성장인자 신호전달 단백의 발현에 관한 면역조직화학적 연구", 대한악안면성형재건외과학회지, 28(6), pp.499~510 (2006), 대한악안면성형재건외과학회
- Younes MN, "Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model", Mol Cancer Ther, 5, pp.2696~2705 (2006)
- Agulnik M, "Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and", or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands, 2007, pp.25, 3978~3984
- Dahse R, "Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas", Br J Cancer, 100, pp.623~625 (2009)
- Dahse R, "KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas", Oral Oncol, 45, pp.826~829 (2009)
- Rothenberg ML, "Topoisomerase I inhibitors: review and update", Ann Oncol, 8, pp.837~855 (1997)
- Rivory LP, "Irinotecan (CPT-11): a brief overview", Clin Exp Pharmacol Physiol, 23, pp.1000~1004 (1996)
- Larsen AK, "DNA topoisomerase I in oncology: Dr. Jekyll or Mr. Hyde?", Pathol Oncol Res, 5, pp.171~178 (1999)
- Saijo N, "Preclinical and clinical trials of topoisomerase inhibitors", Ann N Y Acad Sci, 922, pp.92~99 (2000)
- Friedman HS, "emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors", Cancer, 97(9), pp.2359~2362 (2003)
- Rothenberg ML, "A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma", Cancer, 85, pp.786~795 (1999)
- Ross PJ, "Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma", Clin Oncol (R Coll Radiol), 21(4), pp.311~314 (2009)
- 박영욱, "마우스에서 타액선암 동위종양 모델 제작을 위한 실험적 연구", 대한구강악안면외과학회지, 33(2), pp.81~93 (2007), 대한구강악안면외과학회
- 박영욱, "구강 편평상피세포암 마우스 모델에서 상피성장인자 수용체 억제제를 적용한 분자표적치료", 대한악안면성형재건외과학회지, 31(1), pp.8~17 (2009), 대한악안면성형재건외과학회
- Raynal C, "Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation", Mol Cancer, 9, pp.46~ (2010)
- Louvet C, "A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT-11) in previously pretreated metastatic colorectal cancer patients", Bull Cancer, 91, pp.279~284 (2004)
- Kokawa K, "Neoadjuvant chemotherapy with irinotecan and mitomycin-C for locally advanced squamous cell carcinoma of the uterine cervix", Anticancer Res, 27, pp.2721~2727 (2007)
- Mrozek E, "Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)", Ann Oncol, 19, pp.1417~1422 (2008)
- Argiris A, "Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group", Cancer, 115, pp.4504~4513 (2009)
- Bastos BR, "Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cell lung cancer", J Thorac Oncol, 5(4), pp.533~539 (2010)
- Ciardiello F, "Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225", Clin Cancer Res, 5, pp.909~916 (1999)
- Huang SM, "Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck", Cancer Res, 59, pp.1935~1940 (1999)
- Buchsbaum DJ, "Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation", Int J Radiat Oncol Biol Phys, 54, pp.1180~1193 (2002)
- Bonner JA, "Prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high does radiation therapy with and without cetuximab", J Clin Oncol, 22, pp.5507~ (2004)
- Harari PM, "Epidermal growth factor receptor inhibition strategies in oncology", Endocr Relat Cancer, 11, pp.689~708 (2004)
- Gill GN, "Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity", J Biol Chem, 259, pp.7755~7760 (1984)
- Prewett MC, "Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts", Clin Cancer Res, 8, pp.994~1003 (2002)
- Koizumi F, "Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib “( Iressa”) and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells", Int J Cancer, 108, pp.464~472 (2004)
- Kim S, "Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice", Clin Cancer Res, 12, pp.600~607 (2006)